A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

NCT03559257 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

463

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Galcanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company